abusesaffiliationarrow-downarrow-leftarrow-rightarrow-upattack-typeburgerchevron-downchevron-leftchevron-rightchevron-upClock iconclosedeletedevelopment-povertydiscriminationdollardownloademailenvironmentexternal-linkfacebookfiltergenderglobegroupshealthinformation-outlineinformationinstagraminvestment-trade-globalisationissueslabourlanguagesShapeCombined Shapelocationmap-pinminusnewsorganisationotheroverviewpluspreviewprofilerefreshnewssearchsecurityPathtagticktooltiptwitteruniversalityweb

Esta página não está disponível em Português e está sendo exibida em English

História

Oxfam report says top drug companies focusing on patents, not the poor

In November 2007, Oxfam issued a report, "Investing for life: Meeting  poor people's needs for access to medicines through responsible business practices".  In the report, Oxfam examines the business conduct of 12 pharmaceutical companies with respect to access to medicines for the poor.  The Business & Human Rights Resource Centre invited all 12 companies to respond to the report.  The results to date are below (any future responses received will be added to this page).

On 6 February 2008 Oxfam sent a rejoinder, commenting on the company responses: "Oxfam rejoinder" [DOC]

COMPANY RESPONSES / NON-RESPONSES:

Abbott Laboratories statement [DOC]

AstraZeneca statement [DOC]

Bristol-Myers Squibb did not respond

GlaxoSmithKline statement [DOC]

Eli Lilly declined to respond

Johnson & Johnson statement [DOC]

Merck statement [PDF]

Novartis statement [DOC]

Pfizer statement [DOC]
Pfizer's Malaria Platform [DOC]

Roche declined to respond

Sanofi-Aventis statement [PDF] 

Wyeth did not respond

 

Oxfam Gets A Cold Shoulder From Drugmakers, Pharmalot, 5 Feb 2008 (article commenting on Oxfam's report, the companies' responses, and Oxfam's rejoinder)

Drug makers reject Oxfam targets, in Ethical Corporation, Mar 2008 (scroll down to middle of article)

Respostas da empresa

Abbott Laboratories Ver resposta
AstraZeneca Ver resposta
Bristol-Myers Squibb

Sem resposta

Eli Lilly

Sem resposta

GlaxoSmithKline Ver resposta
Johnson & Johnson Ver resposta
Merck Ver resposta
Novartis Ver resposta
Pfizer Ver resposta
Roche

Sem resposta

Sanofi Ver resposta
Wyeth (part of Pfizer)

Sem resposta

Story Timeline